Deepak Nitrite Ltd (DEEPAKNTR) Q2 FY27 Earnings Call: Record Revenue Rs. 3,091 Cr, Rs. 11,700 Cr Capex Through FY30

Best-Ever Quarter in Five Decades, Led by Phenolics

• Record revenue of Rs.3,091 crore — Q2 FY 2026-2027 consolidated revenue up 19% QoQ and 61% YoY, the best quarterly and half-yearly revenue and EBITDA in over five decades of operations, achieved despite a volatile global chemical backdrop.
• EBITDA of Rs.643 crore (+187% YoY, +16% QoQ) — margin sustained at 21%; PBT Rs.543 crore and PAT Rs.398 crore, up 16% and 15% sequentially respectively.
• H1 FY 2026-2027 revenue of Rs.5,682 crore (+48% YoY) — EBITDA Rs.1,197 crore (+173% YoY) at 21% margin vs ~11% in H1 FY 2025-2026; PAT Rs.743 crore (+221% YoY).
• Phenolics delivered highest-ever quarterly revenue of Rs.2,291 crore — +72% YoY, +29% QoQ, with EBIT of Rs.515 crore (~22% EBIT margin), driven by international supply chain disruptions, higher landed import costs and firm domestic demand.
• Advanced Intermediates revenue of Rs.811 crore (+38% YoY) — but EBIT declined to Rs.49 crore from Rs.67 crore in Q1 FY 2026-2027 (6% margin) on input price headwinds, customer volume variation and duties/logistics/freight impact.
• Balance sheet strengthened — net worth Rs.6,521 crore; net debt Rs.1,657 crore (vs Rs.1,676 crore in Q1); net debt-to-equity improved to 0.25x from 0.27x; cash conversion cycle down to 53 days from 57 days.
• Management flagged that external market conditions will continue to influence near-term profitability, and geopolitical uncertainties and price volatility may persist.

Record Spreads, Doubled Feedstock Costs, No Super Cycle

• Phenolics H1 FY 2026-2027 EBIT of Rs.933 crore — already surpassing the previous highest annual segment EBIT of Rs.867 crore registered in FY22; management believes the segment will set a new annual benchmark by end of FY 2026-2027.
• Propylene cost ~2x usual price — over H1 FY 2026-2027 Deepak in many cases paid possibly close to double the index to proactively secure supply amid geopolitical circumstances; Q2 volumes were roughly flat YoY on feedstock constraints, not capacity, with elevated summer temperatures also impacting production.
• Asset capability near 4 lakh tonnes per annum — Q2 FY 2026-2027 ran below that annualized level, though "not significantly less"; winter months expected to aid throughput, with sustained profitability expected in Q3 FY 2026-2027.
• No super cycle, per management — capacities announced years ago in China and Southeast Asia have already come online; current strength reflects buoyant domestic demand plus geopolitical disruptions to material movement.
• Government duty action favored local manufacturers — the government removed the import duty on phenol and reinstated it in Q2 FY 2026-2027; management said such measures create opportunity for local manufacturers.
• India phenol demand ~6 lakh tons (~600 KT) — growing ~6-7% annually (period unspecified); management does not see China participating in India's phenol landscape in the short-to-medium term and sees no significant disturbance from a new domestic entrant.
• Deepak is now India's largest acetone consumer — as of Q2 FY 2026-2027; captive acetone consumption ability is ~60-65% of production in FY 2026-2027, inclusive of MIBK/MIBC offtake.

Import-Driven Dip, Guided Recovery Through FY28

• Q2 pressure stemmed from sodium nitrite and nitro aromatics imports — customers, seeing market prices rather than Deepak's imported cost, preemptively imported significant volumes that landed in July; most consumers have since returned and orders are being placed at an accelerated rate.
• Integrated upstream assets ran above 100% utilization — from September 2026 (Q2 FY 2026-2027) onwards, with further ramp-up planned via operational excellence initiatives.
• AI EBIT guided at ~Rs.240 crore in FY 2026-2027 — rising to ~Rs.400-420 crore in FY 2027-2028 with upside available; Q3 FY 2026-2027 EBIT% expected between Q1 and Q2 levels (closer to Q1), with Q4 better than Q3.
• 14-15% EBIT margin targeted for AI in FY 2027-2028 — vs ~11% currently per the analyst, with all commissioned assets at steady state; management expects FY28 to be a normalized year with relatively optimized utilization.
• Incremental AI EBIT expected to be more contractual and less volatile — formula-linked with cost pass-through clauses; trial volumes already being supplied from commercial assets.
• Fluorination capex completed at Rs.300 crore — new assets "up-engineered" for aromatic and pyridine fluorination, delinking Deepak from customer campaign schedules; Deepak Chemtech also commissioned a chlorination unit and specialty chemicals plant at Dahej toward the end of Q2 FY 2026-2027.
• MIBK/MIBC utilization at ~60% — management confident of reaching 100% and exceeding it at short notice (period unspecified); MIBK is running at ~100% capacity currently (FY 2026-2027) per CFO Sanjay Upadhyay; REACH registrations received in Deepak's name, enabling export participation in Europe.

Rs.11,700 Crore Program Through FY30, Resin in FY29

• Cumulative capex of Rs.11,700 crores — CFO corrected the analyst's Rs.11,500 crores figure; spend program runs through FY 2029-2030, with the phenol-to-polycarbonate investment the lion's share of capex.
• Capex guidance restated by the CFO — Rs.2,200-2,400 crores in FY 2027-2028, Rs.2,500 crores in FY 2028-2029, and the balance of Rs.2,500-3,000 crores in FY 2029-2030.
• H1 FY 2026-2027 capex of ~Rs.700 crores — with a further Rs.800-900 crores guided for H2 FY 2026-2027; equity funding essentially complete with only ~Rs.50 crores remaining to be injected, and banks to begin funding from H2 FY 2026-2027.
• FY29 commissioning target reaffirmed for the polycarbonate resin plant — the FY30 reference in the investor deck pertains to the fully integrated propylene-to-polycarbonate commissioning, tied to feedstock (PDH plant) availability.
• Fully optimized polycarbonate utilization expected in FY31 — the asset will "probably" be close to optimally utilized by the time upstream integration is done, running on bought-out intermediate in the meanwhile.
• General polycarbonate resin imports were about 2 lakh tons in FY 2025-2026 — running even higher currently; management will sell resin into this market alongside higher-priced compounds.
• Compound approvals progressing across electronics, mobility and defense — long validation cycles apply to compounds, not resins; management expects India's defense market size to be substantially larger 18 months down the line (≈FY 2028-2029).

Beyond Polycarbonate: CDMO in Execution, Two New Investments

• CDMO is "already in execution," not planning — personal care and, in some cases, ag chem products are CDMO opportunities; new plants run technology deployed at industrial scale for the first time in the world, with the opportunity having come via customer collaboration.
• Multifold R&D expansion from kilo lab to pilot to semi-commercial scale — investment "not material" versus revenue/profit; includes hard-to-master chemistries (organometallic, imide manufacturing) targeting purity from 99.9% to 99.999% for high-end, low-volume, extremely high-value applications.
• Management cited growth drivers rather than confirming analyst figures — asked whether 12-15% revenue growth and 18-20% EBITDA margins can be sustained post-FY27 until polycarbonate integration, management did not directly confirm those figures.
• New investments commissioned only in the last few months of FY 2026-2027 — yet to contribute on a full annualized basis; the solvents basket (MIBK, MIBC, acetophenone) has only now come into play; management is "looking at a substantial improvement" in the Advanced Intermediates business.
• Two additional investments in advanced stage — for products where Deepak has a "very high right to win" due to integration, chemistry and customer value; design engineering is already done and investment will begin once these are locked out.
• New AHF and ultra-pure DHF plant housed in a separate entity — not a Deepak Nitrite subsidiary; will supply AHF to Deepak Nitrite for captive consumption and sell into solar and electronics applications.

Cautiously Optimistic Amid Anti-Involution Campaign

• Essentially no Chinese participation in the phenolic segment — management reaffirmed the Q2 FY 2026-2027 investor presentation flag that surplus Chinese capacities continue to exert pressure on global chemical markets.
• Chinese government has taken several steps to rein in overcompetition — management said the anti-involution campaign targets "destructive tendencies to overcompete and destroy value at every stage," and that India — and Deepak in particular — will be able to get the advantage of this; he noted the campaign sometimes operates in a "monolithic tendency" where the government instructs private companies what to do.
• Resurgence in chemistries such as nitro aromatics — as the crackdown on gray-scale/illegal manufacturing shapes up, with buoyant domestic as well as Western demand and, in many cases, enhanced demand for Deepak's products within China itself.
• Management remains "cautiously optimistic" — acknowledging Chinese capacity is world-scale, substantial and efficient, but stressing that efficiency of scale does not necessarily mean efficiency of profitability.
• Improvement visible across the ammonia-to-amines and propylene-to-polycarbonate chains — Deepak currently participates up to phenol and its downstreams and will participate further downstream (polycarbonate) in the future.
• India positioned as consumption anchor with China plus one / de-risking opportunity — management cited China as the world's largest producer, exporter and "dumper" of chemicals, but said this does not define India's opportunity base; no quantitative guidance was provided in the closing remarks, with conversations over Q3 FY 2026-2027 and the next few quarters expected to center on accretive value addition.